|
rs17069665
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further analyses were performed to explore associations of rs17069665 and rs9400241 with ALL susceptibility in terms of age, gender, immunophenotype, minimal residual disease (MRD), and other clinical characteristics.
|
31691337 |
2020 |
|
rs9400241
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As for rs9400241, the effects were more predominant in children < 10 years, and in patients with pre B ALL, positive MRD, anemia, or hepatomegaly.
|
31691337 |
2020 |
|
rs104894229
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition to WT1 overexpression, other MRD positive markers were: NPM1 (Type A, B, K), DNMT3A (R882H), MLL-PTD, IDH1 (R132H) and KRAS (G12S).
|
30457973 |
2019 |
|
rs121913500
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition to WT1 overexpression, other MRD positive markers were: NPM1 (Type A, B, K), DNMT3A (R882H), MLL-PTD, IDH1 (R132H) and KRAS (G12S).
|
30457973 |
2019 |
|
rs121913530
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition to WT1 overexpression, other MRD positive markers were: NPM1 (Type A, B, K), DNMT3A (R882H), MLL-PTD, IDH1 (R132H) and KRAS (G12S).
|
30457973 |
2019 |
|
rs377577594
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A<sup>mut</sup>).
|
28643785 |
2018 |
|
rs387907272
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These observations suggest that ddPCR can sensitively detect the MYD88 L265P mutation in cell-free DNA and could be used as non-invasive diagnostics, but may not be applicable for monitoring minimal residual diseases in PCNSL.
|
29151258 |
2018 |
|
rs1077858
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs in <i>SLCO2B1</i> associated with significant differences in tissue abiraterone (rs1789693, <i>P</i> = 0.0008; rs12422149, <i>P</i> = 0.03) and higher rates of minimal residual disease (tumor volume < 0.5 cc; rs1789693, 67% vs. 27%, <i>P</i> = 0.009; rs1077858, 46% vs. 0%, <i>P</i> = 0.03).
|
28389510 |
2017 |
|
rs12422149
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs in <i>SLCO2B1</i> associated with significant differences in tissue abiraterone (rs1789693, <i>P</i> = 0.0008; rs12422149, <i>P</i> = 0.03) and higher rates of minimal residual disease (tumor volume < 0.5 cc; rs1789693, 67% vs. 27%, <i>P</i> = 0.009; rs1077858, 46% vs. 0%, <i>P</i> = 0.03).
|
28389510 |
2017 |
|
rs1789693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs in <i>SLCO2B1</i> associated with significant differences in tissue abiraterone (rs1789693, <i>P</i> = 0.0008; rs12422149, <i>P</i> = 0.03) and higher rates of minimal residual disease (tumor volume < 0.5 cc; rs1789693, 67% vs. 27%, <i>P</i> = 0.009; rs1077858, 46% vs. 0%, <i>P</i> = 0.03).
|
28389510 |
2017 |
|
rs2838958
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multiple Cox regression analyses revealed associations of minimal residual disease (MRD) at day 33 (hazard ratio 3.458; P = 0.002), MRD at day 78 (hazard ratio 6.330; P = 0.001), SLCO1B1 rs4149056 (hazard ratio 12.242; P < 0.001), and SCL19A1 rs2838958 (hazard ratio 2.324; P = 0.019) with EFS.
|
28525903 |
2017 |
|
rs4149056
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multiple Cox regression analyses revealed associations of minimal residual disease (MRD) at day 33 (hazard ratio 3.458; P = 0.002), MRD at day 78 (hazard ratio 6.330; P = 0.001), SLCO1B1 rs4149056 (hazard ratio 12.242; P < 0.001), and SCL19A1 rs2838958 (hazard ratio 2.324; P = 0.019) with EFS.
|
28525903 |
2017 |
|
rs1051266
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three variants were significantly associated with MRD: rs1544410 in VDR (MRD-day15); rs1051266 in RFC (MRD-day33, MRD-week12), independently and in an additive effect with rs10519613 in IL15 (MRD-day33).
|
27427275 |
2016 |
|
rs10519613
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three variants were significantly associated with MRD: rs1544410 in VDR (MRD-day15); rs1051266 in RFC (MRD-day33, MRD-week12), independently and in an additive effect with rs10519613 in IL15 (MRD-day33).
|
27427275 |
2016 |
|
rs1544410
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three variants were significantly associated with MRD: rs1544410 in VDR (MRD-day15); rs1051266 in RFC (MRD-day33, MRD-week12), independently and in an additive effect with rs10519613 in IL15 (MRD-day33).
|
27427275 |
2016 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The thymidine kinase inhibitor vemurafenib, which inhibits the V600E mutant of BRAF, was reported to induce a CR in multiply relapsed and refractory HCL, with nearly complete clearing of MRD.
|
23892906 |
2013 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The thymidine kinase inhibitor vemurafenib, which inhibits the V600E mutant of BRAF, was reported to induce a CR in multiply relapsed and refractory HCL, with nearly complete clearing of MRD.
|
23892906 |
2013 |
|
rs1057519743
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906.
|
22368272 |
2012 |
|
rs201478192
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The combination of ARMS-PCR and capillary electrophoresis enables quantitative assay of JAK2 V617F mutation, which helps in chronic MPD diagnosis and estimation of minimal residual disease.
|
19215672 |
2009 |
|
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings indicate that there is an effect of the 2677G>T/A polymorphism on progression-free survival in ovarian cancer patients who are treated with a taxane/carboplatin, which is dependent on the extent of residual disease, with a better prognosis for patients with the 2677T/A allele and minimal residual disease.
|
18765553 |
2008 |
|
rs1057520009
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Therefore, it was proposed that the XPO1 E571K variant may serve as a minimal residual disease tool in this setting.
|
28196522 |
2017 |
|
rs1057520009
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To conclude, the detection of the XPO1 E571K mutation in biopsy and plasma cell-free DNA by digital PCR may be used as a novel biomarker in classical Hodgkin lymphoma for both diagnosis and minimal residual disease, and pinpoints a crucial role of XPO1 in classical Hodgkin lymphoma pathogenesis.
|
27479820 |
2016 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In addition to WT1 overexpression, other MRD positive markers were: NPM1 (Type A, B, K), DNMT3A (R882H), MLL-PTD, IDH1 (R132H) and KRAS (G12S).
|
30457973 |
2019 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A<sup>mut</sup>).
|
28643785 |
2018 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We identified 24 DNMT3A R882H mutated patients out of 134 acute myeloid leukemia screened samples and we analyzed in these patients the kinetics of minimal residual disease after induction and consolidation therapy.
|
25554589 |
2015 |